CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT). There will be 2 study...
Phase 3
Dallas, Texas, United States and 5 other locations
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Dallas, Texas, United States and 15 other locations
phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety pr...
Phase 1
Irving, Texas, United States and 25 other locations
compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive ...
Phase 2
Dallas, Texas, United States and 35 other locations
evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors...
Phase 2
Dallas, Texas, United States and 21 other locations
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma whic...
Phase 3
Dallas, Texas, United States and 38 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
Dallas, Texas, United States and 21 other locations
(with enzalutamide-naïve metastatic castration-resistant prostate cancer) will be randomized to receive either NUV-868 monotherapy, enzaluta...
Phase 1, Phase 2
Dallas, Texas, United States and 30 other locations
stomach cancer, gastroesophageal junction cancer, (GEJ cancer) or pancreatic cancer. GEJ is where the t...
Phase 1
Dallas, Texas, United States and 34 other locations
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2....
Phase 1
Dallas, Texas, United States and 14 other locations
Clinical trials
Research sites
Resources
Legal